Cryoport, Inc. · NASDAQ:CYRX
Cryoport — Q1 2024 Earnings Presentation
19 slides from Cryoport's earnings presentation, May 7, 2024
Slide 1: Q1 2024 Earnings Call
Q1 2024 Earnings Call May 7, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of t
Slide 3: Presenters
Jerrell Shelton Robert Stefanovich CEO - Cryoport CFO, SVP - Cryoport Mark Sawicki, Ph.D. Thomas Heinzen Chief Scientific Officer – Cryoport VP Investor Relations and and CEO - Cryoport Systems Corporate Development - Cryoport
Slide 4: Summary
Summary A leading global provider of supply chain solutions for cell & gene therapies that enable manufacturers, Business description contract manufacturers (CDMO’s), contract research organizations (CRO’s), developers, and researchers to carry out their respective business with certainty. • Biophar
Slide 5: Cryoport, Inc. Organization
Cryoport, Inc. Organization (NASDAQ: CYRX) © 2024 CRYOPORT, INC. CONFIDENTIAL |5
Slide 6: Cryoport – Q1 2024 Snapshot
Cryoport – Q1 2024 Snapshot Performance Global Platform (2) over 50 Facilities Globally $54.6 MM $242- $252 MM $448.5 MM in 17 Countries Q1-2024 Revenue FY 2024 Revenue Cash & Short-Term Guidance investments C> Supply Chain Leader Over 3,000+ Global Clients 15 +9% YoY 675 1,100+ Employees Commerci
Slide 7: Growing Cell & Gene Therapy Pipeline
Growing Cell & Gene Therapy Pipeline ✓675 clinical trials (net) in aggregate Clinical Trials Supported by Trial ✓ 77 Phase III trials in the Americas, EMEA and APAC Phase as of 3/31/24 Increased by 21 trials (net) over Q1 2023 Source: Company materials cross-referenced to clinical trial information
Slide 8: Cryoport Commercial Support – Now 15
Cryoport Commercial Support – Now 15 © 2024 CRYOPORT, INC. 8
Slide 9: CGT Clinical Trials by Phase and Region
CGT Clinical Trials by Phase and Region © 2024 CRYOPORT, INC. CONFIDENTIAL |9
Slide 10: A Unified Network Supporting the Life Sciences
A Unified Network Supporting the Life Sciences 17 countries > 50 locations US IE Brentwood, Tennessee Dublin Irvine, California PL Morris Plains, New Jersey Warsaw Houston, Texas Ball Ground, Georgia PH New Prague, Minnesota Manila Valley Stream, New York KR Huntington Beach, California Seoul Chicag
Slide 11: Cryoport's Services Offering
Cryoport’s Services Offering © 2024 CRYOPORT, INC. CONFIDENTIAL | 11
Slide 12: Cryoport Revenue Drivers
Cryoport Revenue Drivers Services revenue 67% of total revenue in Q1 2024 Q1 2023 Revenue Q1 2024 Revenue Product Services 33% 43% Product 57% Services 67% © 2024 CRYOPORT, INC. CONFIDENTIAL | 12
Slide 13: Cryoport Revenue Drivers
Cryoport Revenue Drivers BioStorage/BioServices Commercial Cell and Gene Revenue Therapy Revenue ($ in millions) ($ in millions) $5.4 $3.5 $3.2 $5.0 Q1 2023 Q1 2024 Q1 2023 Q1 2024 © 2024 CRYOPORT, INC. CONFIDENTIAL | 13
Slide 14: Revenue by Type
Revenue by Type © 2024 CRYOPORT, INC. CONFIDENTIAL | 14
Slide 15: Balance Sheet
Balance Sheet Source: Reference goes here © 2024 CRYOPORT, INC. CONFIDENTIAL | 15
Slide 16: Statement of Operations
Statement of Operations © 2024 CRYOPORT, INC. CONFIDENTIAL | 16
Slide 17: Adjusted EBITDA
Adjusted EBITDA © 2024 CRYOPORT, INC. CONFIDENTIAL | 17
Slide 18: Upcoming Investor Conferences
Upcoming Investor Conferences Host Conference Date Location Healthcare Crossroads Leerink May 28-30, 2024 Austin, TX Conference Jefferies Healthcare Conference June 5-6, 2024 New York Roth 10th Annual Conference June 25-27, 2024 London Morgan Stanley 22nd Global Healthcare September 4-6, 2024 New Yo
Slide 19: Cryoport
O Cryoport Enabling the Future of Medicine . " , Me iS le — — ——